Source:http://linkedlifedata.com/resource/pubmed/id/15723353
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-5-18
|
| pubmed:abstractText |
We carried out Genechip analysis using prostate cancer and non-malignant tissue to identify specific genes related to prostate cancer. We focused on neuroserpin (PI-12), which has been identified as one of the genes with high expression in prostate cancer. We analyzed the relationship between its expression pattern and clinical characteristics. Prostate cancer and normal prostate tissue were analyzed by Affymetrix GeneChip technology. We carried out real-time quantitative PCR on a total of 102 specimens: 45 of normal prostate, 45 of previously untreated prostate cancer (constituting 45 pairs of samples obtained at radical prostatectomy, with each pair dissected from the same prostate specimen) and 12 of recurrent hormone refractory prostate cancer (HRPC). Results showed that the neuroserpin gene was more highly expressed in prostate cancer than in normal prostate tissue. Neuroserpin expression in untreated prostate cancer was significantly higher than that in normal prostate. In HRPC it was significantly higher than that in untreated prostate cancer and normal prostate. In untreated prostate cancer, neuroserpin expression was significantly higher in high grade tumors such as poorly differentiated adenocarcinoma than in lower grade tumors such as well or moderately differentiated adenocarcinoma. Higher neuroserpin expression was associated with shorter recurrence-free survival after radical prostatectomy, shorter recurrence-free survival in HRPC patients and shorter overall survival in HRPC patients. The neuroserpin gene may be associated with the development, progression and aggressiveness of prostate cancer. Our present data suggests that higher neuroserpin expression may predict an unfavorable outcome after radical prostatectomy or hormone therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0020-7136
|
| pubmed:author |
pubmed-author:FujinamiKiyoshiK,
pubmed-author:HamadaKenjiK,
pubmed-author:HasumiHisashiH,
pubmed-author:IshiguroHitoshiH,
pubmed-author:KubotaYoshinobuY,
pubmed-author:MiyoshiYasuhideY,
pubmed-author:NakamuraMasashiM,
pubmed-author:OsadaYutakaY,
pubmed-author:SugiuraShinpeiS,
pubmed-author:UemuraHirojiH,
pubmed-author:Yamada-OkabeHisafumiH,
pubmed-author:YaoMasahiroM
|
| pubmed:copyrightInfo |
Copyright 2005 Wiley-Liss, Inc.
|
| pubmed:issnType |
Print
|
| pubmed:day |
20
|
| pubmed:volume |
115
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
911-6
|
| pubmed:dateRevised |
2007-7-24
|
| pubmed:meshHeading |
pubmed-meshheading:15723353-Disease Progression,
pubmed-meshheading:15723353-Disease-Free Survival,
pubmed-meshheading:15723353-Humans,
pubmed-meshheading:15723353-Male,
pubmed-meshheading:15723353-Neuropeptides,
pubmed-meshheading:15723353-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:15723353-Polymerase Chain Reaction,
pubmed-meshheading:15723353-Prognosis,
pubmed-meshheading:15723353-Prostatic Neoplasms,
pubmed-meshheading:15723353-Serpins,
pubmed-meshheading:15723353-Survival Rate,
pubmed-meshheading:15723353-Up-Regulation
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival.
|
| pubmed:affiliation |
Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
|
| pubmed:publicationType |
Journal Article
|